What sets us apart
A clear path from science to impact
Our lead program: CTX1000
Celosia’s lead program is a first-in-class gene therapy targeting toxic TDP-43 in ALS and FTD, currently in IND submission with first-in-patient dosing expected in Q3 2025.
What is TDP-43?
TDP-43 is a protein that helps keep nerve cells healthy, but in ALS and FTD it ends up in the wrong place, becomes toxic, and damages those cells.
Other programs
Celosia is advancing additional programs in ALS (CTX2000), Alzheimer’s disease (CTX3000), and epilepsy syndromes (CTX4000).
Our pipeline
Meet our team
Dr Kathryn Sunn
PhD, CEO
Yazi Diana Ke
PhD, Inventor / Chief Operating Officer
Professor Lars M Ittner
MD, Founder / Chief Scientific and
Medical Officer